From significance of the study to Public health relevance:
Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.
Research findings to Therapeutic opportunity:
This study suggests, for the first time, that a pharmaceutical mixture(DHAASA) encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA), by regulating the expression of its target genes, it may increase the expression of tumor/metastatic suppressors BTG2 and INK4a (fig. 1).
Thereby, it may: (a) inhibit cell cycle progression; and (b) suppress migration, invasion and metastasis of cancer cells. [easy_payment currency=”USD”]
Given the mechanism of action of DHAASA , it may be an ideal anti-metastatic agent to (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy.
Taken together, this study suggests that oncologists may consider treating terminally ill metastatic cancer patients with Docosahexaenoic acid (DHA) and Aspirin (ASA) , as it may stall the progression of advanced metastatic cancers.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D
Undisclosed mechanistic information: How a pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BTG2 and INK4a
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA) increases the expression of tumor/metastatic suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 22/February/2018, 12.06 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com